Posttransplant Allosensitization in Low Immunological Risk Kidney and Kidney-Pancreas Graft Recipients

Table 1

Baseline characteristics and events at 6-months posttransplant for all patients and between anti-HLA (−) and anti-HLA (+) antibodies groups.

Variables	All patients; 𝑁=408	anti-HLA (−); 𝑁=337	anti-HLA (+); 𝑁=71	𝑃 value
Recipient variables
Age (years), mean ± SD	43.5±15.2	44.4±14.7	39.1±17.2	0.02
Female gender, 𝑛 (%)	133 (32.6%)	105 (31.2%)	28 (39.4%)	0.18
Time on dialysis (mo), median (IQR)	41.0 (17.4–74.3)	41.8 (17.9–75.1)	28.4 (10.9–53.8)	0.06
Previous blood transfusions, 𝑛 (%)	130 (31.9%)	107 (31.8%)	23 (32.4%)	0.92
Females with previous pregnancies, 𝑛 (%)	56 (42.1%)	47 (44.8%)	9 (32.1%)	0.29
KP recipients, 𝑛 (%)	68 (16.7%)	50 (14.8%)	18 (25.4%)	0.03
Donor variables
Age (years), mean ± SD	44.5±15.6	45.8±14.7	38.3±18.3	<0.01
Female gender, 𝑛 (%)	143 (35.0%)	117 (34.7%)	26 (36.6%)	0.82
Living donor, 𝑛 (%)	76 (18.6%)	65 (19.3%)	11 (15.5%)	0.46
Transplantation variables
ABDR HLA mismatches, mean ± SD	3.89±1.41	3.82±1.43	4.21±1.25	0.02
ABDR mismatches >3, 𝑛 (%)	261 (64.0%)	211 (62.6%)	50 (70.4%)	0.21
Cold ischemia time (h), median (IQR)	14.7 (10–18.2)	14 (9.5–18)	16.5 (11–19)	0.91
Induction therapy
ATG use, 𝑛 (%)	114 (27.9%)	81 (24.0%)	33 (46.5%)	<0.01
Basiliximab use, 𝑛 (%)	256 (62.7%)	222 (65.9%)	34 (48.6%)	0.01
No induction, 𝑛 (%)	38 (9.3%)	34 (10.1%)	4 (5.6%)	0.37
Posttransplant events at 6-mo
Blood transfusions, 𝑛 (%)	29 (7.1%)	22 (6.5%)	7 (9.9%)	0.31
Delayed graft function, 𝑛 (%)	73 (17.9%)	58 (17.2%)	15 (21.1%)	0.43
Acute rejection, 𝑛 (%)	44 (10.8%)	29 (8.6%)	15 (21.1%)	<0.01
Steroid-sensitive, 𝑛 (%)	22 (5.4%)	17 (5.0%)	5 (7.0%)	0.50
Steroid-insensitive, 𝑛 (%)	22 (5.4%)	12 (3.5%)	10 (14.1%)	<0.01

HLA: human leukocyte antigen; SD: standard deviation; mo: months; IQR: interquartile range; KP: kidney-pancreas; h: hours; ATG: anti-thymocyte globulin.